Cost-Effectiveness Analysis of Alemtuzumab In Comparison With Natalizumab, Intramuscular Interferon Beta-1a, Subcutaneous Interferon Beta-1b, And Fingolimod for The Treatment of Relapsing-Remitting Multiple Sclerosis In Iran
Abstract
Authors
S Taheri N Yousefi MA Sahraian G Mehralian